Related Experiment Video
Updated: Feb 28, 2026
Porcine Liver Transplantation Without Veno-Venous Bypass As an Extended Criteria Donor Model
Published on: August 17, 2022
The Effect and Safety of Prostaglandin Administration in Pediatric Liver Transplantation
Céline Lironi1, Valérie A McLin2, Barbara E Wildhaber1
1Division of Pediatric Surgery, Geneva University Hospitals, University Center of Pediatric Surgery of Western Switzerland, Geneva, Switzerland.
Insights
Dinoprostone administration after pediatric liver transplantation (LT) did not significantly impact ischemia-reperfusion injury (IRI) or liver function. This study found no clear beneficial or harmful effects of dinoprostone in pediatric liver recipients.
Area of Science:
- Pediatric Hepatology
- Transplantation Immunology
- Pharmacology
Background:
- Prostaglandins, like dinoprostone, are used post-liver transplantation (LT) to mitigate ischemia-reperfusion injury (IRI), aid liver recovery, and prevent thrombosis.
- While their benefits in adults are debated, existing pediatric data is limited and suggests no significant impact.
- This study specifically investigated dinoprostone's effects in pediatric liver recipients.
Purpose of the Study:
- To evaluate the efficacy and safety of dinoprostone in pediatric liver transplant recipients.
- To determine if dinoprostone influences post-transplant IRI, hepatic function, or hemodynamic stability.
Main Methods:
- A retrospective analysis of 41 pediatric patients (<16 years) undergoing LT between March 2008 and December 2013.
- Dinoprostone was administered at doses ranging from 0.1 to 0.6 μg/kg/hour for up to 5 days post-LT.
- Key outcomes assessed included post-LT IRI markers, hepatic function tests, factor V levels, and hypotensive episodes up to 60 days.
Main Results:
- Dinoprostone administration, at doses up to 0.6 μg/kg/hour, showed no significant improvement in liver function tests or factor V levels.
- No significant association was found between dinoprostone dosage and the number of hypotensive episodes.
- One patient experienced transient hypotension, potentially linked to dinoprostone, but overall safety profile appeared neutral.
Conclusions:
- This study found no significant beneficial or harmful effects of dinoprostone, at the tested dosages, on IRI markers, hepatic function, or hypotension in pediatric liver transplant recipients.
- Both high and low doses of dinoprostone administered immediately after pediatric LT did not demonstrate a clear impact.
- Further research may be needed to explore other prostaglandin analogs or alternative strategies for managing post-LT complications in children.
Background:
Prostaglandins are often administered after liver transplantation (LT) to diminish ischemia-reperfusion injury (IRI), to favor liver recovery and to prevent vascular thrombosis. Possible beneficial effects in adult liver recipients are controversial, but the single existing pediatric small case series shows no significant impact of prostaglandin administration after LT. The purpose of this study was to analyze the effect of the prostaglandin dinoprostone in pediatric liver recipients.
Methods:
A retrospective analysis of 41 children (<16 years) who underwent LT between March 2008 and December 2013 was performed. Dinoprostone was administered at a rate from 0.1 to a maximum of 0.6 μg/kg per hour immediately after LT and for a maximum of 5 days. Effect of dinoprostone on post-LT IRI and hepatic function up to 60 postoperative days and number of hypotensive episodes were analyzed.
Results:
The median cumulative dose of dinoprostone was 28 μg/kg (interquartile range, 23.2). Dinoprostone had no significant effect on post-LT liver function tests and factor V levels at any of the administered dosages. There was no significant association between the total quantity of vasopressor given and the number of hypotensive episodes observed in 8 patients. One patient showed a short-lasting hypotension, possibly related to the administration of dinoprostone.
Conclusions:
This study did not show, at any dosage between 0.1 and 0.6 μg/kg per hour, any differences in beneficial or harmful effects of high- or low-dose dinoprostone administered immediately after pediatric LT on markers of IRI, hepatic function, or hypotension.
More Related Videos
12:27Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
Published on: May 7, 2015
16:19Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
Published on: September 13, 2014
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption